Verona Pharma plc (LON: WRP) has brought forward the timing for top-line data readouts for its ongoing clinical trials in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) following clinical development updates, the company revealed on Tuesday.
The Phase 2b clinical trial of nebulised RPL554 for COPD maintenance treatment is now expected to report top-line data in the second quarter of 2018, brought forward from mid-2018.
The four-week, double-blind, placebo-controlled, parallel group Phase 2b study involved around 400 patients with moderate-to-severe COPD and took place at numerous sites across Europe. The aim of the study was to investigate the efficacy, safety and dose-response of nebulised RPL554.
Verona Pharma has also brought forward reporting of top-line data from the Phase 2a pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial of RPL54 for CF to the late first quarter of 2018, from the first half of 2018.
The double-blind, placebo-controlled, cross-over Phase 2a study is evaluating the PK and PD profile and tolerability of a single nebulised dose of RPL554 and the effect on lung function in 10 patients with CF.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera